E156: The Future of Clinical Trials, $18m Series A and Breaking Bottlenecks - Meri Beckwith (Co-founder Lindus Health)
In this week’s episode, Meri shares his journey from the world of investing to breaking the bottlenecks in clinical trials as he builds the anti-CRO for life science pioneers.
We discussed:
🔄 Transitioning from venture capital into healthtech
💼 Investor vs Founder Traits, Personality and Mindset
🌱 The origin story of Lindus Health
🏗️ The first few days/weeks of building Lindus Health
🚧 Barriers to entering the pharma industry as a new startup
🔒 Securing the first clinical trial with Habitual
🍾 The bottle necks of clinical trials
🔍 The process of recruiting patients for clinical trials
❌ Where central organisations and institutions go wrong for clinical trials
🤖 The role of AI in the pharma industry
💰 Fundraising a $18m Series A with investments from the likes of Peter Thiel
🔒 How to prevent being replaced by the board and investors
🏢 How to build a healthy culture and team
🤝 How to become a great CEO and deal with co-founder conflicts
💊 Why do pharma need CROs for clinical trials and why become the anti-CRO
Meri Beckwith is the co-founder of Lindus Health and previously a venture capital investor and partner to biotech and digital health companies. He took part in the COVID-19 vaccine trials as a volunteer, where he saw trail outcomes could be improved by focusing on patient experience.
-------------------------------------
Powered by Peerr
Peerr is a healthtech platform connecting the health and life sciences industry through content and thought leaders, KOLs and SMEs.
www.peerr.io
-------------------------------------
YouTube:Amz & Abdul
Twitter -@ScrubbedIn_
Instagram - @Scrubbedin_
Follow us on Instagram & Twitter
Hello@scrubbedin.co.uk
Create your
podcast in
minutes
It is Free